IGFBP2 and central nervous system cancer: IGFBP2 carries Arg-Gly-Asp (RGD) domain that binds to integrins like α5β1 for glioma cell migration, while RGD → RGE mutant (D306E) IGFBP2 could not interact directly with integrin α5 resulting in losing cell mobility[15].